Xanadu Quantum Technologies has partnered with the University of Alberta to apply quantum algorithms to cancer drug discovery, aiming to overcome traditional computational limitations. While this collaboration strengthens Xanadu's investment narrative by demonstrating real-world applications in oncology, the company still faces challenges with recurring revenue, significant net losses, and potential dilution risks from its US$1 billion shelf registration. Investors are advised to consider the high valuation and diverse fair value estimates, along with underlying financial data, before making investment decisions.
S
Read full storySimply Wall Street
Original source
